Goldman Sachs Lifts Roche Holding Price Target Amid Earnings Expectations
Roche Holding stock dipped on September 15, 2026, after Goldman Sachs raised its price target. The shares were trading at around CHF 358 on the SIX Swiss Exchange, a 0.9% drop from the previous day's close of CHF 361.40. This minor pullback comes after a notable surge the day before, with Roche Holding stock jumping 5.0% to CHF 361.40.
The price increase was driven by positive Tam-Peli phase III trial results, which investors responded to enthusiastically. Goldman Sachs analyst James Quigley reaffirmed his Neutral rating on Roche Holding and increased the 12-month price target from CHF 349 to CHF 366.
This new target is still below the average analyst estimate of around CHF 373.71 for Roche shares, implying a potential upside of roughly 3.4% from the previous close. Analysts are also keeping an eye on Roche's earnings trajectory, with experts estimating that the company could report earnings of CHF 20.41 per share for fiscal year 2026.